Zacks Investment Research upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

Several other research firms also recently weighed in on GRFS. BidaskClub downgraded GRIFOLS S A/S from a hold rating to a sell rating in a research report on Wednesday, January 30th. Berenberg Bank downgraded GRIFOLS S A/S from a buy rating to a hold rating in a research report on Friday, February 8th. Finally, Morgan Stanley lowered their target price on GRIFOLS S A/S from $20.00 to $19.00 and set an underweight rating on the stock in a research report on Wednesday, January 2nd. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. GRIFOLS S A/S has an average rating of Hold and an average target price of $21.00.

NASDAQ GRFS opened at $19.48 on Friday. The firm has a market cap of $13.48 billion, a P/E ratio of 16.65, a P/E/G ratio of 1.40 and a beta of 1.07. The company has a current ratio of 2.77, a quick ratio of 1.22 and a debt-to-equity ratio of 1.30. GRIFOLS S A/S has a fifty-two week low of $17.42 and a fifty-two week high of $24.97.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Moody National Bank Trust Division raised its holdings in GRIFOLS S A/S by 3.7% during the fourth quarter. Moody National Bank Trust Division now owns 22,460 shares of the biotechnology company’s stock valued at $412,000 after acquiring an additional 810 shares during the period. Cardinal Capital Management raised its holdings in GRIFOLS S A/S by 1.6% during the fourth quarter. Cardinal Capital Management now owns 52,853 shares of the biotechnology company’s stock valued at $970,000 after acquiring an additional 814 shares during the period. Advisors Asset Management Inc. raised its holdings in GRIFOLS S A/S by 58.0% during the fourth quarter. Advisors Asset Management Inc. now owns 3,629 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 1,332 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in GRIFOLS S A/S by 45.3% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,770 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 1,799 shares during the period. Finally, Hansberger Growth Investors LP raised its holdings in GRIFOLS S A/S by 2.3% during the fourth quarter. Hansberger Growth Investors LP now owns 103,925 shares of the biotechnology company’s stock valued at $1,908,000 after acquiring an additional 2,294 shares during the period. Institutional investors own 19.96% of the company’s stock.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on GRIFOLS S A/S (GRFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.